Chan FC et al. - The biology of classical Hodgkin lymphoma (cHL) at the time of relapse was investigated in an effort to identify novel and robust prognostic biomarkers after autologous stem-cell transplantation (ASCT). Indeed, a novel clinically applicable prognostic assay was developed that identifies patients with unfavorable post-ASCT outcomes at the time of first relapse.